... so sorry, page-41

The cognitive and executive function was disappointing..

However if patients weren't showing clearly significant symptoms to begin with and there was variability in how each of the patients had started their decline, can make it very difficult to record statistical sigificant trends. I think Prana alluded to the fact in the conference call there was high variability in the group- which is not going to help data correlation.

Even though the patients - like Mr Lawler -may be feeling they were benefitting from the trials there may be no way to get a statistical measure of the benefit. All that can be learned is where to target the next trial to ensure success ..

I hope there is some good news for all of us in the future when more about the trial data is revealed that give clear path forward ...

i still believe in the potential of PBT2 as a treatment... but i need more information on what the next steps are to protect further investment.